Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus SOX as first-line treatment for unresectable advanced or recurrent gastric cancer
ChiCTR2000029691Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, tegafur and oxaliplatin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Progression-free survival. Started Feb 2020; status: recruiting.
02
Drugs
camrelizumabtegafuroxaliplatin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000029691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029691.